• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alnylam Pharmaceuticals Inc.

    4/4/25 4:30:17 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email
    DEFA14A 1 alny2025proxyamendment.htm DEFA14A Document

     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. 1)
     
     
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
     
    ☐Preliminary Proxy Statement
     
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 
     
    ☐Definitive Proxy Statement
     
    ☒  Definitive Additional Materials
     
    ☐    Soliciting Material under §240.14a-12 
    Alnylam Pharmaceuticals, Inc.
    image_0.jpg
    (Name of Registrant as Specified in Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
     
    ☒No fee required
     



    ☐Fee paid previously with preliminary materials
     
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 
     
     
     
    AMENDMENT NO. 1 TO PROXY STATEMENT
    FOR THE ANNUAL MEETING OF STOCKHOLDERS
    TO BE HELD ON MAY 8, 2025
    This Amendment No.1 to the Proxy Statement (this “Amendment”) amends the definitive proxy statement filed by Alnylam Pharmaceuticals, Inc. (the “Company”) with the U.S. Securities and Exchange Commission (“SEC”) on March 24, 2025 (the “Proxy Statement”) and made available to the Company’s stockholders in connection with the solicitation of proxies by the Company’s Board of Directors (the “Board”) for use at the Company’s Annual Meeting of Stockholders, scheduled to be held on May 8, 2025 at 8:30 A.M. (Eastern Time) (the “Annual Meeting”). This Amendment is being filed with the SEC on April 4, 2025.
    This Amendment clarifies certain disclosure in the Proxy Statement on the vote requirements for Proposal 2, “To approve an amendment to our Restated Certificate of Incorporation allowing for officer exculpation” (“Proposal 2”). The vote required to approve Proposal 2 is the approval of a majority of the outstanding shares of common stock of the Company. Abstentions and broker non-votes, if any, will have the same effect as a vote “Against” Proposal 2.
    Except as specifically amended herein, all information in the Proxy Statement remains unchanged. No other changes have been made to the Proxy Statement. If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote. This Amendment should be read in conjunction with the Proxy Statement. 
    ******
    The description of the vote required to approve Proposal 2 on page 71 of the Proxy Statement under the heading “Vote Required” is hereby amended and restated in its entirety as follows:
    The affirmative vote of the holders of a majority of the outstanding shares of our common stock is required to approve the Charter Amendment. Abstentions and broker non-votes, if any, will have the same effect as a vote “Against” Proposal 2. If the proposed Charter Amendment is not approved by the affirmative vote of the holders of a majority of the outstanding shares of our common stock, then the proposed Charter Amendment will not be adopted, and our Charter will not eliminate or limit monetary liability for our officers.
    ******
    The paragraph under the heading “Vote Required to Approve Each Item on the Proxy” on page 86 of the Proxy Statement is hereby amended and restated in its entirety as follows:
    Vote Required to Approve Each Item on the Proxy
    You may vote “for,” “against” or “abstain” on proposals 1, 2, 3, 4 and 5. Abstentions and broker non-votes are included in the determination of the number of shares present at the annual meeting for determining whether a quorum is present at the meeting but are not counted as shares cast. Accordingly, abstentions and broker non-votes, if any, would have no effect on the vote for Proposals 1, 3, 4 and 5, because these Proposals are based on a percentage of the votes that are actually cast at the annual meeting. Abstentions and broker non-votes will have the same effect as votes “Against” Proposal 2.

    Get the next $ALNY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY

    DatePrice TargetRatingAnalyst
    8/4/2025Underperform → Peer Perform
    Wolfe Research
    8/4/2025$490.00Perform → Outperform
    Oppenheimer
    7/30/2025$370.00Outperform
    Raymond James
    7/21/2025$385.00Buy
    Truist
    3/31/2025$353.00Buy
    Redburn Atlantic
    3/24/2025$280.00 → $328.00Neutral → Overweight
    Analyst
    11/12/2024Peer Perform → Underperform
    Wolfe Research
    10/16/2024Sector Outperform
    Scotiabank
    More analyst ratings

    $ALNY
    SEC Filings

    View All

    SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.

    10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    7/31/25 8:11:22 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    7/31/25 8:05:29 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    6/18/25 4:48:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

    - Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST)- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain, from August 29 - September 1, 2025. These presentations will highlight the potential of RNAi therapeutics to transform the treatment of cardiovascular disease and reinforce Alnylam's commitment to advancing innovative therapies for patients living with rare and more prevalent conditions underserved by

    8/11/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference, on Tuesday, August 12, 2025 at 8:00 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam (NASDAQ:ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and pre

    8/5/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil

    7/31/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

    9/20/23 2:36:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

    2/17/23 12:30:09 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Reitan Colleen F bought $10,363 worth of shares (36 units at $287.85), sold $8,383 worth of shares (36 units at $232.86) and was granted 775 shares (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    5/12/25 4:05:00 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alnylam Pharma upgraded by Wolfe Research

    Wolfe Research upgraded Alnylam Pharma from Underperform to Peer Perform

    8/4/25 8:14:44 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharma upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Alnylam Pharma from Perform to Outperform and set a new price target of $490.00

    8/4/25 8:14:34 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Alnylam Pharma with a new price target

    Raymond James resumed coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $370.00

    7/30/25 7:32:36 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP Chief R&D Garg Pushkal was granted 2,851 shares and sold $1,299,746 worth of shares (2,851 units at $455.89) (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    8/19/25 5:28:53 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Tanguler Tolga was granted 2,851 shares and sold $632,759 worth of shares (1,396 units at $453.27), increasing direct ownership by 5% to 29,466 units (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    8/19/25 5:28:18 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Financial Officer Poulton Jeffrey V. was granted 4,644 shares and sold $1,030,727 worth of shares (2,274 units at $453.27), increasing direct ownership by 5% to 50,121 units (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    8/19/25 5:27:52 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Leadership Updates

    Live Leadership Updates

    View All

    Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

    3/5/25 7:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

    As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th

    3/5/24 9:06:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Announces Appointment of Peter Kellogg to Board of Directors

    – Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi

    3/8/23 7:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/12/24 9:50:12 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/8/24 10:34:33 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    8/12/24 9:40:06 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Financials

    Live finance-specific insights

    View All

    Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil

    7/31/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2025 results as well as expectations for the future via conference call on Thursday, July 31, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuti

    7/17/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered

    5/1/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care